Patent ID: 8697681
Filing Date: 2014-04-15
Classification: A61K,A61P,C12Q

Abstract:
1. A therapeutic method for treating a patient with gastric cancer, comprising: measuring an expression level of dihydropyrimidine dehydrogenase gene in a biological sample that is obtained from the patient; determining whether the expression level of dihydropyrimidine dehydrogenase gene in the biological sample is higher than a corresponding cut-off point; administering a combination chemotherapy of cisplatin and a combination drug of tegafur/gimeracil/oteracil potassium to the patient if the said expression level is higher than the said predetermined cut-off point, wherein the predetermined cut-off point is a value selected from the following: [1] an average or median value of the expression level of dihydropyrimidine dehydrogenase gene in the TS-1/cisplatin combination group or in patients undergoing combination chemotherapy with 5-FU/cisplatin; [2] a value in which the hazard ratio of the TS-1/cisplatin combination group to the 5-FU/cisplatin combination group is minimal; [3] a value in which the difference in 2-year survival rate between the TS-1/cisplatin combination group and the 5-FU/cisplatin combination group is maximal; [4] a value in which the hazard ratio of the TS-1/cisplatin combination group to the 5-FU/cisplatin combination group is not greater than a certain value; and [5] a value in which P-value of the log-rank test for the survival time of the 5-FU/cisplatin combination group and the TS-1/cisplatin combination group is minimal or less than a certain level.